MN-001

Phase 2Small molecule

MMediciNova

MN-001 is one of 123 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Interstitial CystitisActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

Interstitial CystitisPhase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Idiopathic Pulmonary Fibrosis

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Phase 3

2 2

Tracleer

Johnson & Johnson

Phase 3

2 3

Prevacid

Takeda

Phase 3

1 4

Letairis

Gilead

Phase 3

1 5

Gleevec

Novartis

Phase 3

1 6

MS Contin

Merck & Co.

Phase 3

—7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 8

Coumadin

AAbbott

Phase 3

1 9

Minocin

TTriax

Phase 3

1 10

Bactrim

UUniversity of California, San Francisco

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Non-Alcoholic Fatty Liver Disease

NCT05464784

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis1 trial

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

Completed·MMediciNova·Phase 2·NCT02503657·15 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Active, not recruiting·MMediciNova·Phase 2·NCT05464784·40 enrolled

Interstitial Cystitis1 trial

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

Completed·MMediciNova·Phase 2·NCT00295854·296 enrolled

NAFLD1 trial

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

Completed·MMediciNova·Phase 2·NCT02681055·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for MN-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MN-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MN-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MediciNova company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMediciNova

MN-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Interstitial Cystitis1 trial

NAFLD1 trial

References

Drug Info

Quick Facts

Related News